Dimethylformamide → N-methyl-1-(9-methyl-6-morpholino-8-((4-(oxetan-3-yl)piperidin-1-yl)methyl)-9H-purin-2-yl)-1H-benzo[d]imidazol-2-amine

Participants

Reaction Steps

A mixture of 2-chloro-9-methyl-6-morpholin-4-yl-8-(4-oxetan-3-yl-piperidin-1-ylmethyl)-9H-purine (100 mg, 0.25 mmol), (1H-benzoimidazol-2-yl)methyl-amine (43 mg, 0.29 mmol), Pd2dba3 (6 mg, 0.006 mmol), Xphos (12 mg, 0.025 mmol) and cesium carbonate (121 mg, 0.37 mmol) in DMF (2 mL) was purged with argon gas then subjected to microwave irradiation at 145° C. for 30 min. The reaction mixture was loaded onto an Isolute® SCX-2 cartridge (10 g), which was washed with MeOH/DCM before the desired product was eluted with 2 M NH3 in MeOH/DCM. The product was collected and concentrated in vacuo. The resultant residue was purified by flash chromatography (Si—PPC, DCM:MeOH 100:0 to 99:1 to 98:2) to afford 447 as a cream foam (58 mg, 45%). LCMS (Method I): RT=2.36 min, M+H+=518. 1H NMR (CDCl3, 400 MHz) δ 8.51 (bs, 1 H); 8.29 (d, J=7.9 Hz, 1 H); 7.51 (d, J=7.9 Hz, 1 H); 7.19 (t, J=7.8 Hz, 1 H); 7.08 (t, J=7.8 Hz, 1H); 4.75 (dd, J=7.9, 6.1 Hz, 2 H); 4.46 (t, J=6.1 Hz, 2 H); 4.33 (m, 4 H); 3.92-3.85 (m, 7H); 3.73 (s, 2 H); 3.26 (d, J=4.9 Hz, 3 H); 2.88 (m, 2 H); 2.78-2.69 (m, 1 H); 2.15 (m, 2H); 1.66 (m, 3 H) and 1.19-1.07 (m, 2 H)

Provenance & Evidence